Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are correct. Many are grasping to make this worse than it is. This is the DTC's way to get information they want fast. Absolutely no worries here.
Everything is coming together for SNDY. FDA plus CE Mark certification on all current products and future developed products. That alone is worth every penny I have invested.
GLTA true longs!
Well said and all fact.
GLTU and all true longs.
I hate to be the bearer of bad news but company CEOs rarely make business decisions based on whether or not the investors will approve. That's business and if you can't stomach that then move on.
The CEO's job is to keep the company running and make a profit. The company has been running for a long time and during the course of the past two years every earnings report has reported a profit. Nothing huge yet, but a profit all the same; even with their primary focus being on getting international certification.
Yes, the company has been diluting to continue paying bills. I would rather them do that than come up delinquent on bills. That alone tells me that this company is not a scam. It is a legitimate company who above all has enough sense to pay their bills on time.
I recommend not only focusing on the micro economics and taking a look at the macro economics of it all.
Everything I have read tells me the company is steadfast on getting their products internationally certified in order to sell globally and increase their bottom line. Will it sell in Europe? Who knows, but I say yes. I do not conduct research to persuade anyone here. Just for myself in deciding on where to put my money.
That is all
According to Dun & Bradstreet, They rate SNDY as a "Moderate risk" but state that all payments are paid within 14 days beyond terms. Annual sales of $1 million and they currently have 8 employees.
SNDY currently has no pending bankruptcies, judgments, liens, or law suits against them.
SNDY has no negative experiences and no payments placed in collections.
All not bad at all.
This Dun & Bradstreet information is public information and can be accessed at www.dnb.com. You will have to pay for the report. I paid $61 for the report I just outlined.
If you are curious about SNDY's "other products" I suggest going on their website.
As far as distribution lines I suggest contacting the company. At this time most of their primary customers are US Government and academic institutions.
The good thing is that everything going on with SNDY is well beyond this message board. Patience and a little trust.
Despite the past, I do not see anything going on with SNDY that makes me question my decision to invest. Business as usual.
I recommend some put away their Business 101 books and try reading some Business 200, 300, and 400 level books.
GLTA
This statement is absolutely valid and correct IMO.
Some are looking at this the wrong way. Just because SNDY does not have people beating down there door (yet) for there products does not mean the products are not good. The American medical market and the EU medical market are very different.
I recommend people just sit back, wait, and see.
Nothing is worse than basing your research on preconceived biases.
GLTA
Because the Mammoview is a very specific medical procedure that has not yet been fully adopted by medical facilities within the US.
The predominant Mammoview customers in the US have been government organizations and a few universities, all in a research realm.
There has been some reporting of hospitals using it but I would suspect that it is related to these institutions.
Many of the articles on studies I have read states that the commonly used mammography screening has provided similar results in identifying breast cancer lesions as the Mammoview. However using the mammography has yielded a 25% misdiagnosis in properly identifying lesions where the Mammoview has not. For what ever reason many US medical facilities, so far, have mitigated this 25% deficiency and have not replaced their dated mammography screening machines with the Mammoview. Yet.
I do not see this as being the case in Canada and in Europe for two reason. 1, According to a Global Cancer report, there are far more new cancer diagnosis and misdiagnosis in Canada and The European Union than there are in the US annualy. 2, Canada and the EU have establish socialized medicine programs that are working hard to eliminate the growing breast cancer epidemic.
I believe that Canada and the EU will adopt the Mammoview as the standard breast cancer early detection system and over time the US will follow suite. Especially as the Mammoview continues to evolve and the mammography becomes more obsolete.
All in my opinion of course.
GLTA
Nice find! Goes to show that the Mammoview is not the "failure" some would like us to believe. This is just one example of the evolving technology that the Mammoview is.
IMO this technology will become more mainstream in the US once it is proven in the EU. Many medical facilities within the US are reluctant to change, especially when it comes with a price tag. This is why it has only been prominent in government and educational facilities. Once it is approved in the EU and proven, medical facilities in the US will be forced to play catch up. Larger companies know this and are waiting for final CE Mark approval before making their move. We will have to wait and see what that move is.
Patience is key anyway you look at it.
GLTA patience longs.
This is an assumption.
Actions are based on existing conditions. The company's current existing conditions are completely different from what they were during prior R/S's. Therefore this argument is not valid.
For one I do not spread "tales." After receiving the FDA approval and since 2010 the company's primary focus is to get all products CE Mark certified. Plain and simple.
Sales? Do you expect them to get FDA approved and start selling these things at Sears? No! The Mammoview is a revolutionary product who's primary costumers have been the US National Institution of Health (NIOH) and the National Cancer Institute (NCI). Both US Government institution.
Let me put on my Chief Operations Officer hat here. Hmmmm, so if my primary customers are government institutions, perhaps countries with socialized medicine, ie government, would be interested in my products. Hmmm. What do I need for that? Oh I know, the CE Mark for Europe as well as the certification in Canada. Why? Because privatized medicine in the US is generally pleased with their results in spotting and treating breast cancer therefore less Likely to pursue other technologies. Europe and Canada are another story. Most European countries rate much higher than the US in breast cancer incidence, to include Canada, and their early detection methods are lacking.
Both NIOH and NCI agree that non-evasive ductoscopic procedures are the preferred method of breast cancer early detection. Less evasive and less expensive. Once this is proven in the EU and Canada, reconfirmed by US government institutions, private medical treatment facilities in the US will begin purchasing. I believe that although it started here in the US, the technology has to be proven in the EU (Socialized medicine) before it will take off in the US.
All it takes is one piece of great news to turn this thing around. The facts that support this company's vision and business plan are astonishing.
I am not at all concerned about delution, prior RS, or employee salaries. None of this compares to the potential of this company by way of its products, product development, product certification, and global interest in these products.
All of this is my opinion but I can assure you it comes from my personal DD. Everything I have said can be backed up through your own DD. Guaranteed!
GLTA true longs with vision!
Perhaps that's your problem. No one denies that history is important but that is only 1/3rd of the story. Past, present, and future.
What does the company's past look like? We all agree less than desirable.
What is the company doing now? Continue to improve products, new product development, FDA approval (complete) and CE Mark certification on all products.
What is the company's vision for the future? Merger and or acquisition.
This is a no brainer. By all means continue to regurgitate the same historical information but without the present and future you are only hurting yourself.
GLTA
The fact that this is a masters level thesis does not take away from the validity of the product. Not to mention that the student was from one of the top business schools in the world.
If anything the fact that this is a thesis increases the validity because the writer is not writing with any pre-existing biases.
This was just another piece of DD someone has provided, taken it or leave it.
If merger/ acquisition was the goal for each R/S, it did not work out too well. So (to me) the very reason you give for a 5th R/S is why I do not believe they will do it gain. That tactic has not worked in the past so why would they try again? It's simple, they won't!
Oh and the biggest difference between now and then is that whole CE mark thing. By having all their products FDA approved and CE Mark certified is worth it's weight in gold. Plain and simple.
Keep spinning all you want but in the end the facts are the same. Many here have laid these facts out and things that you are focusing on really will not matter in the end.
Everyone's perception might be different but this is mine and from what I have read it is not too far off from most here.
If it seems bleak than move out. As I have said before, this is how I see this company.
SNDY has had a rocky past, no doubt. 20 years (1986 to 2006) looking for their niche, while selling standard endoscopy products. Like many companies they go public, in their case 2006, to open up another financial stream. Many do this in the pinkies, and of course many fail.
In April 2006, after their merger with ViaDux Healthcare, the niche was found and they focused on revolutionizing Mammary ductoscopy. This means more focus on R&D while sales remained stagnant. A risky call but good one for the long run.
I believe that in 2010 SNDY had every intention of getting the CE Mark completed after receiving FDA approval in 2009. (I also believe getting the CE Mark was always their next goal after FDA approval, not the hope that sales in the US would fly.) At this point they were selling their other products and working on the SteriTap. Funds fell short and were forced on finishing either the SteriTap or the CE Mark at the time. I do not believe that it was a coincidence that once the SteriTap was announced in Spring 2012, the announcement that the CE Mark would resume came soon after.
Of course things like 4 prior R/S’s are concerning, no one is denying that. What I am saying is that the conditions that led to those R/Ss do not match what they have today. According to Morningstar there has been one R/S after FDA approval in late 2010. I believe this is important fact to the R/S talk. Perhaps when they realized that the CE Mark would be delayed they wanted to see if they could get a buyer/merger quicker with what they had and with a higher PPS? That was what they said in their PR. I believe that we are finally where SNDY intended us to be in 2010.
Regardless we are here now. I do not care about an A/S increase or any threat of another R/S, which I find improbable. The dilution, which may seem high to some, is still pretty average in the grand scheme of things. Regardless it has all been used to move the company forward. This includes contractual agreements and salaries. Not my concern to the least because I understand how business works.
We have FDA approved products and a CE Mark final audit complete. Now we wait for the final word of approval. No worries here.
I suspect, which many have alluded to, once CE Mark certification is confirmed SNDY will be looking for the highest bidder, if they have not already found them. Their primary focus has been to create new products in an up and coming market, get them certified for global sale, and merge with a larger company that can move them to the next level.
If anyone is confused I recommend rereading Aqua's posts. I think they are a very good source of unbiased information using business sense.
All in my opinion of course
Oh by the way, my "brothers" and sisters are only those who volunteer to do something that is bigger than themselves.
GLTA whatever your ambitions are.
Aqua, I think you are spot on.
The company clearly put their focus on receiving the CE Mark after they received FDA approval. They put less emphasis in sales because they realized that Europe and Canada were much better markets and the CE Mark needed to be the priority.
They also realized that getting the CE Mark was a little tougher than they first thought so by hiring the two company's to facilitate the CE Mark process and liaise them in the EU market shows their commitment.
Things are moving forward just as the CEO has laid out. Oh by the way, my under grad was in business.
Please keep posting your thoughts am observations.
GLTU and all true longs.
Great perspective Aqua. I agree with all you have said. Everything Solos has done has followed a basic business plan. I believe that it is pretty obvious that things are stacking just as Solos has intended. Timelines may shift but in the end things continue to happen, as described.
GLTU
That's right, the only thing that matters to most of us here is getting that CE mark married to that FDA approval. That's it. The rest is peripheral.
GLA
You never have to feel bad for me. I have done my DD and know what I own.
This is a very poor assessment in my opinion. I am not sure what "you called" but everyone knows that nothing major will happen until the CE Mark is confirmed.
Today was just the audit and no one, with good sense, thought anything would be announced today. We hoped, but knew it was a long shot.
Patience continues to be key. In the mean time the pps may go down or it may go up, but in my opinion, it will go up once CE Mark is announced and what ever the next step for SNDY is.
GLA
I was a little leery of another delay, as i sure many were, but since we received a letter from the CEO saying that things were right on schedule I have full confidence that we are good to go.
100% success rate of Expert Resources. I am confident that they do not want to tarnish that claim and if there was a delay it would have been identified weeks ago, not the day prior and right after the announcement that all was on track.
GLA
Time lines get delayed all the time in business. Your point is invalid and not even a big deal. As long as it gets done and oh by the way we just got confirmation that everything is on schedule per the last schedule released in June.
Sit back and watch. Resistance is futile.
GTA
If what you refer to as "habitual dilution" is used to move the company closer to meeting it's goals as defined in its business strategy, then yes, I support it. There has not been any indication that dilution has been used negligently.
Besides, the cries that SNDY has diluted huge amounts really is not the case in my opinion. I have seen companies that are legitimately toxic dilute billions and billions in a much shorter time frame than what we have seen here.
SNDY has been very transparent here and in my opinion they are bringing it closer to meeting their main objective here, M/A.
GLA
I seriously doubt it. Good try though.
What has been the primary objective of SNDY the past few years? Product sales or R&D/ national certification/ international certification?
Product sales is clearly not the priority of Solos Endoscopy at this point.
To my opinion SNDY has put everything into the FDA approval and CE Mark of the Mammoview and SteriTap. Once this is complete it ties into the 95% merger/ acquisition statistic of products with both FDA/ CE Mark approved products.
This is call a "business strategy." Anyone who studied business as an undergrad, MBA, or even a class at your local community college can see this.
Unless you follow the company's business strategy you really will not understand why certain decisions are made.
GLTA resilient Longs
Of course biases goes both ways, this is why you have to eliminate your personal biases while conducting research. Gather all information and evaluate in order to draw a final conclusion. Once this is done, do it again to ensure all of your assumptions are either confirmed or denied.
This is how I see this company. SNDY has had a rocky past, no doubt. 20 years (1986 to 2006) looking for their niche, while selling standard endoscopy products. Like many companies they go public, in their case 2006, to open up another financial stream. Many do this in the pinkies, and of course many fail.
In April 2006, after their merger with ViaDux Healthcare, the niche was found and they focused on revolutionizing Mammary ductoscopy.
I believe that in 2010 SNDY had every intention of getting the CE Mark completed after receiving FDA approval in 2009. At this point they were selling their other products and working on the SteriTap. Funds fell short and were forced on finishing either the SteriTap or the CE Mark at the time. I do not believe that it was a coincidence that once the SteriTap was announced in Spring 2012, the announcement that the CE Mark would resume came soon after.
Of course things like 4 prior R/S’s are concerning, no one is denying that. What I am saying is that the conditions that led to those R/Ss do not match what they have today. According to Morningstar there has been one R/S after FDA approval in late 2010. I believe this is important fact to the R/S talk. Perhaps when they realized that the CE Mark would be delayed they wanted to see if they could get a buyer/merger quicker with what they had and with a higher PPS? That was what they said in their PR. I believe that we are finally where SNDY intended us to be in 2010.
Regardless we are here now. I do not care about an A/S increase or any threat of another R/S, which I find improbable. We have FDA approved products and a CE Mark process wrapping up with a company that has a 100% certification rate. These two facts alone hold a high collateral rate.
So in the end I suspect, which many have alluded to, once CE Mark certification is confirmed SNDY will be looking for the highest bidder, if they have not already found them. Their primary focus has been to create new products in an up and coming market, get them certified for global sale, and merge with a larger company that can move them to the next level.
All in my opinion of course
GLTA whatever your ambitions are.
Well said.
GLTY!
That was an awesome post. Well played.
Thanks for compiling this list.
GLTA True Longs!
I am no sure if many people know this buy "most" penny stocks are the same. Granted thy may have a few similar traits they are not. SNDY is not the same company as it was a couple years ago. How do I know? FDA approved products and close to CE mark approval.
Many of SNDY's competitors have a far greater AS than SNDY.
So how were people's portfolios wiped out? The value of the stock does not change, it's a ruse. A 5000 to 1 RS may mean you go from owning 5m shares to 1k but the value is the same. Basic economics right? Not ideal but not the end of the world. Regardless there is no indication of this happening again.
There is no reason for SNDY to RS now. There are companies with far greater AS who have a much higher PPS at this point. SNDY will be fine.
Since 2010 the company's focus was product development with FDA approval. They tried to do the CE Mark in conjunction but realized it was not possible so they put the CE mark on hold.
Once the Mammoview and SteriTap were good to go (Spring 2012) focus returned to the CE Mark. That is what has led us to today.
In 2010 they were a little overzealous and realized all objectives could be met at the same time. Crystal clear to me.
Sit back and relax. The next few weeks will be interesting.
GLTA
There is absolutely no information that supports or warrants a R/S, just someone’s opinion. Even if the A/S is increased, it is still far below that of many of SNDY’s competitors. Any dilution that has been taking place has been VERY MINIMAL in the grand scheme of things and it has gone to support the company’s business objectives. These objectives are product development, product certification, and international sales/distribution. Very clear and simple.
Before 2013 SNDY had not gone through a CE Mark audit. Any argument to what they had or had not done before this time is dated and irrelevant. During 2013 SNDY has passed the first audit and everyday moves closer to the second audit being completed.
During the past few months the primary objective for SNDY has been to get through the second CE Mark Audit. Because of this there has been a lull in communication. I have no doubt this will be explained in the weeks and months ahead.
SNDY has made great strides toward their business objectives the past 18 months.
SNDY is GOLDEN!
Load up now because the clock is ticking.
GLTA that know the facts!
I had no problem opening it up. I cut and pastes it below.
April 22, 2013
OTC Markets Group Inc. 304 Hudson Street, 2nd Floor New York, New York 10013
Re: Solos Endoscopy, Inc. (SNDY)
Dear Sir/Madame:
I have been retained by Solos Endoscopy, Inc., a Nevada corporation (“Company”), for the purpose of rendering this letter to OTC Markets Group Inc. (“OTC Markets”) with respect to the information publicly disclosed by the Company and published in the OTC Disclosure & News Service. OTC Markets is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended (“Securities Act”).
I hereby represent that I am a U.S. resident. I am licensed to practice law in the State of California and I am permitted to practice before the U.S. Securities and Exchange Commission (“SEC”); I have not been prohibited from practice before them. As such, I am permitted to opine on the federal laws of the United States. I have been retained by the Company for the purpose of rendering this letter and related matters solely for the purpose of reviewing the current information supplied by the Company; as such, I was not involved in the drafting of such current information.
In connection with rendering this opinion, I have investigated such corporate records and other documents, and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter. In examining the documents, I have assumed the genuineness of signatures (both manual and conformed), the authenticity of documents submitted as originals, the conformity with originals of all documents furnished as copies and the correctness of facts set forth in such documents.
In addition to the previously reviewed documents as referenced in my Attorney Letters dated April 26, 2012, May 24, 2012, September 10, 2012, and December 14, 2012, I have also reviewed the following documents (“Information”) in connection with the preparation of this letter:
Document Date of Posting on OTC Disclosure & News Service
Annual Financial Statements – Years Ended December 31, 2012 and 2011 April 15, 2013 Annual Disclosure Statement – Year Ended December 31, 2012 April 15, 2013
Based on the examination and inquiry set forth above, I am of opinion that the Information: (a) constitutes “adequate current public information” concerning the common stock of the Company quoted on the OTC Markets (“Securities”) and the Company itself, and “is available” within the meaning of Rule 144(c)(2) under the Securities Act; (b) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended; (c) complies as to form with the OTC Markets’ Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcmarkets.com; and (d) has been posted through the OTC Disclosure & News Service.
The financial statements are not audited and were prepared with the assistance of Fred V. Schiemann, C.P.A., one of the Company’s directors. These statements were then reviewed by management prior to filing. The primary officer reviewing and approving the Company’s financial statements is Robert Segersten, the Company’s President and Chief Executive Officer. Mr. Segersten has a Bachelor of Science degree from Bates College and Juris Doctor degree from Boston University, and has had many years’ experience with public companies and their financial statements.
The Company’s transfer agent is Pacific Stock Transfer Company. (“Transfer Agent”). The Transfer Agent is registered with the SEC. I have confirmed the number of outstanding shares as set forth in this Information by reviewing the records of the Company and the Transfer Agent.
I have previously personally met with management and a majority of the directors of the Company, have reviewed the Information published by the Company through OTC Disclosure & News Service, and have discussed the Information with management and a majority of the directors of the Company.
To my best knowledge, after inquiry of management and the directors of the Company, neither the Company, its officers and directors, any holder of 5% or more of the securities of the Company, nor this counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.
This letter is being delivered to OTC Markets for its sole use and benefit and is not to be used, circulated, quoted or otherwise referred to or relied upon for any other purpose without express written consent, except that OTC Markets has full and complete permission and rights to publish this letter through the OTC Disclosure & News Service for viewing by the public and regulators.
It is understood that I express no opinion as to the applicability to or compliance with any state securities laws and regulations. In addition, this letter is given as of the date set forth above and is restricted to the stated facts and circumstances presented to me and described herein, and that any other or different facts and circumstances might require a different letter by me. I assume no, and hereby disclaim any, obligation to update or supplement this letter to reflect any facts or circumstances that may hereafter come to my attention or any changes in laws that may hereafter occur.
Sincerely,
Brian F. Faulkner
Great post! All fact and proof of good things to come. Those who think otherwise are only fooling themselves.
GLTA true longs!
Great information Mike! Thanks!
GLTA true longs!
It does look good if you are properly doing your DD. The only ones it seems negative to are the ones who sold too soon and are watching from the sidelines. Oh and trying to justify their mistakes to everyone else.
GLTA true longs!
Great post! Thanks for reaching out to them and letting us know. Great news! Today is irrelevant to the big picture.
GLTS true longs!
The only thing that has changed since August is progress. Last year the CEO outlined his plan and we are slowly but surly seeing that plan come into fruition.
A business plan, near debt free, FDA approved products, evolving innovation, growing market, potential partners, ability to sell on global market. The list continues to grow and 99% of every other company on the OTC wished they had half of this going for them.
Things like timelines are goals and nothing more. Proposed targets that more often than not are forced to slide right. It was risky for them to even post it because of the criticism they would, and have, received for missing targets. I see this as being a very bold move by the company as an attempt and desire to keep us, the investors, informed.
Impatient people make rash decisions that they have to live with; although some of them strive to justify to themselves, and others, that they made the correct choices.
SNDY has come a long way and we have the evidence, from the company, to prove that things are coming along. A chill was thrown on the company, they quickly addressed it, and it was removed. Completely transparent. Anyone who can not see this, does not because they do not want to.
The weeks and months ahead are going to be amazing and I am glad I am along for the ride.
GLTA true longs!
I believe that there are a few on this board that are stressing the idea that we are moving up again. Like Highflier and many other have said, you only lose if you sell when you are down. Common sense really.
At one point I was down over half my investment and once again I am up. I realize it could always drop again but IMO that will not happen any time soon.
SNDY is on the right path meeting all of it's goals. Yes we have hit delays But in the grand scheme of things these delays have been minor. The writing is one the wall and we are moving up. Stay patient and you will be rewarded.
This really is a no brainer when you review all the facts.
All IMO of course.
GLTA true longs and those who want to make money!
(Yes this is my one post of the day due to my suspension)
The only people who lost are the ones who sold. Now I bet they regret it as we move back up. right?
Patiences will pay off.
Sorry I will not be able to respond anymore today as I am on a 21 day, 1 post a day, suspension. Thanks!
GLTA true long!
Even if another delay to the CE Mark presents it's self, it will not change my view of the company. Business is business and things happen. As long as the buisness plan continues to move forward I am not concerned.
All IMO and from what I have read, the same opinion as most.
We all have to make a decision and at the end of the day can you live with your decision? Time will tell. My decision has been made.
GLTA true longs!
Hey Penny! Great job with being able to provide a fully substantiated response that explains every challenge the other guy has brought up. Of course we will not be able to change one's opinion when their mind is already made up.
I for one appreciate the great information, and educated explanation, you provide day in and day out.
Clocks ticking and those of us who have stood buy SNDY the past year plus will be rewarded.
Have a great rest of the weekend. Can't wait until Tuesday.
Mike F
GLTA true longs!